J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Want to cut your energy bills? Here’s how five experts are doing it 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
MENLO PARK, Calif., March 02, 2017 -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it will present at the Cowen and Company 37th Annual Health Care Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 4:00 p.m. ET (1:00 p.m. PT) on Monday, March 6, 2017, in Boston. A live audio webcast and replay of the presentation will be available on the Investors section of Dermira’s corporate website at www.dermira.com.
About Dermira
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s product pipeline includes three Phase 3 product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate, in development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); CIMZIA® (certolizumab pegol), in development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; and olumacostat glasaretil, in development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, Calif. For more information, please visit www.dermira.com.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com) and LinkedIn page (https://www.linkedin.com/company/dermira-inc-) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website and LinkedIn page in addition to following its SEC filings, press releases, public conference calls and webcasts.
Contacts: Media: Erica Jefferson Senior Director, Head of Corporate Communications 650-421-7216 [email protected] Investors: Andrew Guggenhime Chief Operating Officer and Chief Financial Officer 650-421-7200 [email protected] Robert H. Uhl Westwicke Partners Managing Director 858-356-5932 [email protected]
